Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BLU
BELLUS Health Inc.
stock NASDAQ

Inactive
Jun 28, 2023
14.74USD0.000%(0.00)3,449,256
Pre-market
0.00USD-100.000%(-14.74)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 17, 2021
09:30AM EST  BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States   Business Wire
Dec 14, 2021
09:37PM EST  BELLUS Health Announces Pricing Of US$200 Mln Public Offering In Canada And U.S.   RTTNews
09:25PM EST  BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States   Business Wire
08:22AM EST  The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks   Benzinga
Dec 13, 2021
04:03PM EST  BELLUS Health Announces Filing Of Prospectus Supplement In connection With Proposed Offering Of Of $175M In Common Shares In Canada And The United States   Benzinga
04:01PM EST  BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States   Business Wire
02:36PM EST  Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher   Benzinga
01:08PM EST  Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge   Benzinga
10:42AM EST  Evercore ISI Group Maintains Outperform on BELLUS Health, Raises Price Target to $20   Benzinga
10:19AM EST  IIROC Trade Resumption - BLU   PR Newswire
10:08AM EST  IIROC Trading Halt - BLU   PR Newswire
10:03AM EST  Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals   Benzinga
09:57AM EST  Watching BELLUS Health; Hearing BTIG Raises Price Target From $13 To $18   Benzinga
07:22AM EST  BELLUS Health Announces Positive Topline Results From Phase 2b SOOTHE Trial Of BLU-5937 For Refractory Chronic Cough   RTTNews
07:04AM EST  BELLUS Health Says its Phase 2b SOOTHE Trial of BLU-5937 Achieved its Primary Endpoint   Benzinga
07:00AM EST  BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough   Business Wire
Dec 7, 2021
08:26AM EST  The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck's HIV Program, Decision Day For Dar   Benzinga
06:46AM EST  RBC Capital Maintains Outperform on BELLUS Health, Raises Price Target to $11   Benzinga
Nov 10, 2021
06:38PM EST  BELLUS Health Q3 EPS $(0.29) Down From $(0.09) YoY, Sales $4.00K Up From $3.00K YoY   Benzinga
04:30PM EST  BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights   Business Wire
07:00AM EST  BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences   Business Wire
Nov 1, 2021
07:00AM EDT  BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937   Business Wire
Oct 18, 2021
08:37AM EDT  RBC Capital Maintains Outperform on BELLUS Health, Raises Price Target to $9   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 23, 2021
07:16AM EDT  BELLUS Health Announces Completion Of Patient Enrollment In SOOTHE Phase 2b Trial For Refractory Chronic Cough And BLUEPRINT Phase 2a Trial For Chronic Pruritus Associated With Atopic Dermatitis   Benzinga
07:09AM EDT  BELLUS Health Complete Patient Enrollment In SOOTHE Phase 2b Trial And Phase 2a BLUEPRINT Clinical Trial   RTTNews
07:00AM EDT  BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis   Business Wire
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 14, 2021
02:49PM EDT  Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb   Benzinga
12:27PM EDT  Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August   Benzinga
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
06:10AM EDT  HC Wainwright & Co. Maintains Buy on BELLUS Health, Raises Price Target to $14   Benzinga
Sep 13, 2021
11:02AM EDT  What's Going On With BELLUS Health's Stock Today?   Benzinga
10:02AM EDT  BELLUS Health shares were trading higher after the company announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough.   Benzinga
09:04AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Sept. 13, 2021: JKS, NEGG, DVAX, BLU, MDXG   Benzinga
07:49AM EDT  BELLUS Health Announces Positive Interim Analysis From Phase 2b SOOTHE Trial Of BLU-5937 In Refractory Chronic Cough   RTTNews
07:47AM EDT  BELLUS Health Announces Interim Analysis From Phase 2b SOOTHE Trial Of BLU-5937 In Refractory Chronic Cough; Says Interim Analysis 'met the threshold for a high probability of clinical efficacy'   Benzinga
07:45AM EDT  BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough   Business Wire
Sep 2, 2021
07:00AM EDT  BELLUS Health to Present at the H.C. Wainwright Global Investment Conference   Business Wire
Aug 23, 2021
07:09AM EDT  BELLUS Health To Report Additional RELIEF Data In Oral Presentation At ERS International Congress 2021   RTTNews
07:00AM EDT  BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021   Business Wire
Aug 11, 2021
04:58PM EDT  BELLUS Health Q2 EPS $(0.23) Down From $(0.14) YoY, Sales $4.00K, Same YoY   Benzinga
04:30PM EDT  BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights   Business Wire
Jul 29, 2021
10:39AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2021   Benzinga
08:08AM EDT  BTIG Initiates Coverage On BELLUS Health with Buy Rating, Announces Price Target of $9   Benzinga
May 25, 2021
07:00AM EDT  BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference   Business Wire
May 12, 2021
07:00AM EDT  BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference   Business Wire
May 10, 2021
05:01PM EDT  BELLUS Health Q1 EPS $(0.20) Down From $(0.18) YoY   Benzinga
04:30PM EDT  BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights   Business Wire
07:03AM EDT  BELLUS Health to Present at the American Thoracic Society 2021 International Conference   Business Wire
May 8, 2021
08:55PM EDT  Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. (BELLUS or the Company) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Apr 27, 2021
10:00AM EDT  PLUG, WKHS & BLU Looming Deadlines: Bronstein, Gewirtz & Grossman   GlobeNewswire Inc
Apr 23, 2021
11:11PM EDT  Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. (BELLUS or the Company) (NASDAQ: BLU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Apr 13, 2021
09:19AM EDT  Lowey Dannenberg, P.C. Announces Filing of Securities Class Action   GlobeNewswire Inc
07:00AM EDT  BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference   Business Wire
Apr 7, 2021
10:28AM EDT  Lowey Dannenberg, P.C. Announces Filing of Securities Class Action   GlobeNewswire Inc
Mar 24, 2021
07:14AM EDT  BELLUS Health Appoints William Mezzanotte To Board   RTTNews
07:00AM EDT  BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors   Business Wire
Mar 19, 2021
03:17PM EDT  Gainey McKenna & Egleston Announces A ClassAction   GlobeNewswire Inc
Mar 17, 2021
09:07PM EDT  Forum Merger IV Corp. Prices IPO Of 30 Mln Units At $10.00/unit   RTTNews
04:57PM EDT  Lowey Dannenberg, P.C. Announces Filing of Securities Class Action   GlobeNewswire Inc
Feb 25, 2021
04:25PM EST  BELLUS Health Reports FY20 Sales $15K Down From $27K YoY   Benzinga
04:02PM EST  BELLUS Health Reports Year 2020 Financial Results and Business Highlights   Business Wire
Feb 22, 2021
07:00AM EST  BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences   Business Wire
Feb 18, 2021
01:09PM EST  IIROC Trade Resumption - BLU   PR Newswire
01:00PM EST  IIROC Trading Halt - BLU   PR Newswire
11:44AM EST  IIROC Trade Resumption - BLU   PR Newswire
11:37AM EST  IIROC Trading Halt - BLU   PR Newswire
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
06:56AM EST  RBC Capital Initiates Coverage On BELLUS Health with Outperform Rating, Announces Price Target of $8   Benzinga
Jan 15, 2021
04:40PM EST  Are You Following Analysts On These Penny Stocks?   Benzinga
Jan 14, 2021
07:00AM EST  BELLUS Health to Present at the Eleventh International Virtual Cough Symposium   Business Wire
Dec 23, 2020
04:53PM EST  BELLUS Health Reports $50M At-The-Market Facility   Benzinga
04:51PM EST  BELLUS Health Establishes At-the-Market Facility   Business Wire
Dec 14, 2020
04:28PM EST  BELLUS Health F-10 Shows Registration For $250M Common Stock Shelf Offering   Benzinga
07:18AM EST  BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis   Benzinga
07:07AM EST  BELLUS Health Says First Patient Dosed In Phase 2 BLUEPRINT Trial Of BLU-5937   RTTNews
07:00AM EST  BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis   Business Wire
Dec 8, 2020
07:13AM EST  BELLUS Health Announces First Patient Dosed In Phase 2b SOOTHE Trial Of BLU-5937 For Treatment Of Refractory Chronic Cough   Benzinga
07:12AM EST  BELLUS Health Announces First Patient Dosed In Phase 2b SOOTHE Trial Of BLU-5937 For Refractory Chronic Cough   RTTNews
07:00AM EST  BELLUS Health Announces First Patient Dosed in its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough   Business Wire
Dec 7, 2020
07:14AM EST  Bellus Health Announces Ramzi Benamar CFO   Benzinga
07:11AM EST  BELLUS Health Appoints Ramzi Benamar As CFO   RTTNews
07:00AM EST  BELLUS Health Appoints Ramzi Benamar as Chief Financial Officer   Business Wire
Nov 24, 2020
07:00AM EST  BELLUS Health to Participate in the Evercore ISI 3rd Annual Virtual HealthCONx Conference   Business Wire
Nov 18, 2020
11:46AM EST  Evercore ISI Group Initiates Coverage On BELLUS Health with Outperform Rating, Announces Price Target of $12   Benzinga
Nov 12, 2020
07:41AM EST  BELLUS Health Q3 Net Loss $5.7 Mln Or $0.09/shr Vs. $6.5 Mln Or $0.14/shr Last Year   RTTNews
07:12AM EST  BELLUS Health Q3 EPS $(0.09) Up From $(0.14) YoY, Sales $3.00K Down From $7.00K YoY   Benzinga
07:00AM EST  BELLUS Health Reports Third Quarter 2020 Financial Results and Business Highlights   Business Wire
Nov 10, 2020
07:00AM EST  BELLUS Health to Participate in Jefferies Virtual London Healthcare Conference   Business Wire
Oct 22, 2020
09:23AM EDT  BELLUS Health Closes $40 Mln Public Offering Of Common Shares   RTTNews
09:20AM EDT  BELLUS Health Closes US$40 Million Public Offering of Common Shares in Canada and the United States, Including Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
Oct 20, 2020
12:57PM EDT  BELLUS Health shares are trading lower after the company announced the launch of a $35 million public offering in Canada and the US.   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger   Benzinga
05:54AM EDT  BELLUS Health Priced 15.5M Share Public Offering @$2.25/Share   Benzinga
Oct 19, 2020
11:34PM EDT  BELLUS Health Announces Pricing Of US$35 Mln Public Offering In Canada And U.S.   RTTNews
11:25PM EDT  BELLUS Health Announces Pricing of US$35 Million Public Offering in Canada and the United States   Business Wire
05:17PM EDT  10 Stocks Moving In Monday's After Hours Session   Benzinga
04:15PM EDT  BELLUS Health Reports Launch Of Public Offering In Canada, US   Benzinga
04:15PM EDT  BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States   Business Wire
Sep 8, 2020
07:09AM EDT  BELLUS Health Announces Design For Phase 2b Trial With BLU-5937 In RefractoryChronic Cough   RTTNews
07:00AM EDT  BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough   Business Wire
Sep 3, 2020
07:00AM EDT  BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences   Business Wire
Aug 14, 2020
08:50AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
06:53AM EDT  HC Wainwright & Co. Maintains Buy on BELLUS Health, Lowers Price Target to $10   Benzinga
Aug 13, 2020
07:18AM EDT  BELLUS Health Q2 EPS $(0.14) Down From $(0.13) YoY, Sales $4.00K Down From $6.00K YoY   Benzinga
07:12AM EDT  BELLUS Health Q2 Net Loss $8.42 Mln Or $0.14/Shr Vs Loss $5.91 Mln Or $0.13/Shr Last Year   RTTNews
07:00AM EDT  BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights   Business Wire
Jul 19, 2020
07:30PM EDT  SHAREHOLDER REMINDER for CVGI, TCMD, and BLU: Block & Leviton LLP   GlobeNewswire Inc
Jul 14, 2020
08:54AM EDT  Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible violations of federal securities laws, and certain investors may have valuable claims. Hagens Berman also encourages persons who may be able to assist the Firms investigation to contact its attorneys.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC